Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

British journal of clinical pharmacology - 1 Mar 2005

Saito Masato, Yasui-Furukori Norio, Uno Tsukasa, Takahata Takenori, Sugawara Kazunobu, Munakata Akihiro, Tateishi Tomonori

Abstract excerpt

AIMS: Lansoprazole is a substrate of CYP2C19 and CYP3A. The aim of this study was to compare the inhibitory effects of clarithromycin, an inhibitor of CYP3A on the metabolism of lansoprazole between CYP2C19 genotypes. METHODS: A two-way randomized double-blind, placebo-controlled crossover study was performed. Eighteen volunteers, of whom six were homozygous extensive metabolizers (EMs), six were heterozygous EMs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Clarithromycin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Drug Interactions

Share to Lansoprazole

Share to Omeprazole

Share to Protein Synthesis Inhibitors

Share to Proton Pump Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 15752376
DOI: 10.1111/j.1365-2125.2004.02329.x
PMCID: PMC1884793

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.PMID 15752376Read ↗

Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.Semantic proximity Read ↗

Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.Semantic proximity Read ↗

CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin.Semantic proximity Read ↗

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Effects of genetic polymorphisms of CYP2C19*2/*3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects.Semantic proximity Read ↗

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.Semantic proximity Read ↗

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.Semantic proximity Read ↗

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.Semantic proximity Read ↗

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.Semantic proximity Read ↗

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.